Adma Biomanufacturing was Adma Biologics’s largest segment in fiscal 2025, bringing in $493.00M of $510.17M (97%).
| Segment | FY 2011 | FY 2012 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biomanufacturing | $144.07M | $249.74M | $415.81M | $493.00M | |||||||||
| Component Of Adma Biomanufacturing That Usually Provides Financial, Operational & Administrative Support And Is Considered An Operating Segment | — | — | — | — | |||||||||
| Plasma Collection Centers | $9.87M | $8.33M | $10.51M | $17.03M | |||||||||
| Component Of Plasma Collection Centers Segment That Usually Provides Financial, Operational & Administrative Support And Is Considered An Operating Segment | — | — | — | — | |||||||||
| Plasma Collection Center | — | — | — | — | |||||||||
| Reconciling Item | $143.00K | $143.00K | $143.00K | $143.00K | |||||||||
| Corporate | — | — | — | — | |||||||||
| Total | $154.08M | $258.22M | $426.45M | $510.17M |
Adma Biologics brought in $510.17M from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 19.6% from $426.45M in fiscal 2024. Adma Biomanufacturing was the largest at $493.00M (96.6%), ahead of Plasma Collection Centers at $17.03M (3.3%) and Reconciling Item at $143.00K (0.0%).
Compared with fiscal 2024, Plasma Collection Centers grew 62.1% to $17.03M and Adma Biomanufacturing grew 18.6% to $493.00M. From fiscal 2022 to 2025, combined revenue from these segments grew from $154.08M to $510.17M, a compound annual growth rate of 49.0%. Adma Biomanufacturing's share of the total rose from 93.5% to 96.6%.
United States was Adma Biologics’s largest region in fiscal 2025, bringing in $503.92M of $510.17M (99%).
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| United States | $146.28M | $244.74M | $410.01M | $503.92M | ||
| International | $7.65M | $13.33M | $16.31M | $6.11M | ||
| Reconciling Item | $143.00K | $143.00K | $143.00K | $143.00K | ||
| Total | $154.08M | $258.22M | $426.45M | $510.17M |
Adma Biologics brought in $510.17M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 19.6% from $426.45M in fiscal 2024. United States was the largest at $503.92M (98.8%), ahead of International at $6.11M (1.2%) and Reconciling Item at $143.00K (0.0%).
From fiscal 2022 to 2025, combined revenue from these regions grew from $154.08M to $510.17M, a compound annual growth rate of 49.0%. United States' share of the total rose from 94.9% to 98.8%.
Product Revenue was Adma Biologics’s largest product and service line in fiscal 2020, bringing in $42.08M of $42.22M (100%).
| Product and Service | FY 2020 |
|---|---|
| Product Revenue | $42.08M |
| License Revenue | $142.83K |
| Total | $42.22M |
Adma Biologics brought in $42.22M from its two product and service lines in fiscal 2020, the year ended December 31, 2020. Product Revenue was the largest at $42.08M (99.7%), ahead of License Revenue at $142.83K (0.3%).
Adma Biologics (ADMA) reports its revenue by segment, by geography and by product and service. In fiscal 2025, Adma Biomanufacturing was its largest segment, bringing in $493.00M (96.6% of the total), followed by Plasma Collection Centers at $17.03M (3.3%).
Adma Biomanufacturing was Adma Biologics' largest segment in fiscal 2025, bringing in $493.00M, or 96.6% of the $510.17M total across its three segments.
United States was Adma Biologics' largest region in fiscal 2025, bringing in $503.92M, or 98.8% of the $510.17M total across its three regions.
Product Revenue was Adma Biologics' largest product and service line in fiscal 2020, bringing in $42.08M, or 99.7% of the $42.22M total across its two product and service lines.
Plasma Collection Centers grew faster than Adma Biomanufacturing in fiscal 2025, up 62.1% from $10.51M to $17.03M. Adma Biomanufacturing grew 18.6% to $493.00M.
Every figure comes from Adma Biologics' annual financial filings, as reported. Each line keeps the name Adma Biologics gives it, and years follow its fiscal calendar.
Adma Biologics' revenue by segment goes back to fiscal 2011, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.